Precision BioSciences 在欧盟两国临床试验申请获批后扩大 Eliminate-B 试验规模

美股速递
Apr 15

生物技术公司 Precision BioSciences 宣布,其针对B细胞恶性肿瘤的CAR-T疗法候选药物 Eliminate-B 的临床试验申请已获得两个欧洲国家的监管批准。基于此项进展,公司决定扩展该项临床试验的覆盖范围。此次扩展将有助于加速该疗法的全球开发进程,并为更多患者提供参与前沿治疗研究的机会。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10